
A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial
Clin. Vaccine Immunol.
Martin et al.
13: 1267
Supplemental material
Files in this Data Supplement:
- Supplemental file 1
-
Table S1 (The median and mean ELISA antibody titers to vaccine antigens), Table S2 (A line listing of the peak ELISA antibody titers against each vaccine antigen for each subject), and Table S3 (The medians, geometric means, and arithmetic means for ELISPOT responses against peptide pools representing each vaccine antigen).
MS Word document, 86K.